Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (DE:RGO)
FRANKFURT:RGO
Regeneron (RGO) Stock Price & Analysis
2 Followers
RGO Stock Chart & Stats
Day’s Range€840.2 - €840.2
52-Week Range― - ―
Previous Close€855.4
Volume0.00
Average Volume (3M)N/A
Market Cap
$92.80B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
€9.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€976.94Price Target Upside16.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Regeneron News
Bulls Say, Bears Say
Bulls Say
Innovation And PipelineRegeneron's unique dual antibody approach in its obesity pipeline, aiming to preserve muscle mass during weight loss, sets it apart from competitors and highlights the company's innovative edge.
Product AdoptionPositive physician feedback and over 100,000 orders for Eylea HD reflect strong market adoption, with the new permanent J-code expected to boost prescribing rates further.
Regulatory DevelopmentsThe FDA's acceptance of Dupixent's supplemental Biologics License Application (sBLA) for priority review in the treatment of COPD could herald a significant expansion of the drug's market.
Bears Say
Drug Approval SetbacksRegeneron's odronextamab faces approval challenges due to the FDA's concerns about confirmatory trials, potentially delaying its market entry.
Legal And Regulatory IssuesThe Department of Justice alleges Regeneron inflated Medicare's drug costs by not reporting credit card processing fees as price concessions.
Market CompetitionIncreased competition from approved CD20xCD3 bispecifics and recent Vabysmo reimbursement in EU5 may lead to significant Eylea sales erosion.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.06% Insiders
33.95% Mutual Funds
23.35% Other Institutional Investors
39.65% Public Companies and
Individual Investors
RGO FAQ
What was Regeneron’s price range in the past 12 months?
Currently, no data Available
What is Regeneron’s market cap?
Currently, no data Available
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is May 02, 2024 which is in 7 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Feb 02, 2024. The company reported €11.171 earnings per share for the quarter, beating the consensus estimate of €10.108 by €1.063.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron does not currently pay dividends.
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is €9.6.
How many shares outstanding does Regeneron have?
Currently, no data Available
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of €11.171 in its last earnings report, beating expectations of €10.108. Following the earnings report the stock price went up 0.803%.
Which hedge fund is a major shareholder of Regeneron?
Among the largest hedge funds holding Regeneron’s share is Dodge & Cox. It holds Regeneron’s shares valued at 2B.
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€976.94 (16.28% Upside)
€976.94 (16.28% Upside)
Blogger Sentiment
Bullish
DE:RGO Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $32.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.81%
12-Months-Change
Fundamentals
Return on Equity
16.26%
Trailing 12-Months
Asset Growth
13.18%
Trailing 12-Months
Company Description
Regeneron
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.
---
RGO Company Deck
---
RGO Earnings Call
Q4 2024
0:00 / 0:00
---
RGO Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
RGO Stock 12 Months Forecast
Average Price Target
€976.94
▲(16.28% Upside)
Technical Analysis
Best Analysts Covering RGO
1 Year
1 Year Success Rate
15/19 ratings generated profit
1 Year Average Return
+15.02%
assigned a buy rating last month
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 78.95% of your transactions generating a profit, with an average return of +15.02% per trade.
---